(Total Views: 289)
Posted On: 07/27/2021 5:36:52 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to ‘significantly increase the potential customer base and lead to multiple long-term collaborations.’” TumorGenesis will use its new lab to produce media as well, among other things. “According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that it will be able to meet the needs of researchers.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to ‘significantly increase the potential customer base and lead to multiple long-term collaborations.’” TumorGenesis will use its new lab to produce media as well, among other things. “According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that it will be able to meet the needs of researchers.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
